Economic implications of obesity among people with atherothrombotic disease

Ademi, Z., Walls, H. L., Peeters, A., Liew, D., Hollingsworth, B., Stevenson, C. E., Steg, P. G., Bhatt, D. L. and Reid, C. M. 2010, Economic implications of obesity among people with atherothrombotic disease, International journal of obesity, vol. 34, no. 8, pp. 1284-1292.

Attached Files
Name Description MIMEType Size Downloads

Title Economic implications of obesity among people with atherothrombotic disease
Author(s) Ademi, Z.
Walls, H. L.
Peeters, A.
Liew, D.
Hollingsworth, B.
Stevenson, C. E.ORCID iD for Stevenson, C. E.
Steg, P. G.
Bhatt, D. L.
Reid, C. M.
Journal name International journal of obesity
Volume number 34
Issue number 8
Start page 1284
End page 1292
Total pages 9
Publisher Nature Publishing Group
Place of publication London, England
Publication date 2010-08
ISSN 0307-0565
Keyword(s) atherothrombosis
direct health-care costs
Summary Objective: The purpose of this study was to ascertain the impact of obesity on the cost of disease management in people with or at high risk of atherothrombotic disease from a governmental perspective using a bottom-up approach to cost estimation. In addition, the aim was also to explore the causes of any differences found.

Method: The health-care costs of obesity were estimated from 2819 participants recruited into the nationwide Australian REACH Registry with established atherothrombotic disease or at least three risk factors for atherothrombosis. Enrollment was in 2004, through primary care general practices. Information was collected on the use of cardiovascular drugs, hospitalizations and ambulatory care services. Bottom-up costing was undertaken by assigning unit costs to each health-care item, based on Australian Government-reimbursed figures 2006-2007. Linear-mixed models were used to estimate associations between direct medical costs and body mass index (BMI) categories.

Results: Annual pharmaceutical costs per person increased with increasing BMI category, even after adjusting for gender, age, living place, formal education, smoking status, hypertension and diabetes. Adjusted annual pharmaceutical costs of overweight and obese participants were higher (7 (P0.004) and 144 (0.001), respectively) than those of the normal weight participants. This was due to participants in higher BMI categories receiving more pharmaceuticals than normal weight participants. There was no significant change across the BMI categories in annual ambulatory care costs and annual hospital costs.

Conclusion: In these participants with or at high risk of atherothrombotic disease, annual pharmaceutical costs were greater in participants of higher BMI category, but there was not such a gradient in the annual hospital or ambulatory care costs. The greater cardiovascular pharmaceutical costs for participants of higher BMI categories remained even after adjusting for a range of demographic factors and comorbidities. Our results suggest that these costs are explained by the higher number of drugs used among people with atherothrombotic disease. Further investigation is needed to understand the reasons for this level of drug use.
Language eng
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Health and Social Development
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in TR Web of Science
Scopus Citation Count Cited 5 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 484 Abstract Views, 4 File Downloads  -  Detailed Statistics
Created: Thu, 09 Aug 2012, 14:56:02 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact